|
Revolade(R) (Eltrombopag) Receives European Marketing Authorisation For The Treatment Of Chronic Imm |
|
|
|
|
Written by Webmaster
|
|
Thursday, 18 March 2010 |
|
More info...
GlaxoSmithKline (GSK) announced that the European Medicines Agency (EMA) has granted marketing authorisation for Revolade (eltrombopag), a once-daily oral treatment for adults with chronic immune thrombocytopenic purpura (ITP).1 Revolade is for patients who have already had their spleen removed (splenectomy) and are not responding to other treatments such as corticosteroids and immunoglobulins ...
Home And Garden Decor Share Your Opinion. (0 posts)
|
|
Last Updated ( Thursday, 18 March 2010 )
|
